Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter,...

Area of Science:

• Pulmonary Medicine
• Interventional Pulmonology
• Medical Devices

Background:

• Severe emphysema necessitates less invasive, non-surgical treatment options.
• The Spiration Valve System (SVS) offers a potential less invasive approach.

Purpose of the Study:

• To evaluate the effectiveness and safety of the Spiration Valve System (SVS) compared to optimal medical management in severe emphysema patients.
• To assess SVS impact on lung function, health status, and exercise capacity.

Main Methods:

• Multicenter, open-label, randomized controlled trial.
• 172 severe heterogeneous emphysema patients (aged ≥40) randomized 2:1 to SVS plus medical management or medical management alone.
• Primary outcome: change in FEV1 at 6 months; secondary outcomes: responder rates, lung volume, hyperinflation, health status, dyspnea, exercise capacity, and safety (composite thoracic serious adverse events).

Main Results:

• Statistically significant improvements in mean FEV1 observed at 6 and 12 months in the SVS group compared to controls.
• Significant improvements in secondary efficacy endpoints (except 6-minute-walk distance) at 6 months.
• Higher incidence of composite thoracic serious adverse events in the SVS group (31.0% vs. 11.9%), mainly due to serious pneumothorax (12.4%).

Conclusions:

• The Spiration Valve System demonstrates significant efficacy in improving multiple outcomes for severe heterogeneous emphysema.
• SVS treatment shows an acceptable safety profile despite an increased risk of serious pneumothorax.
• SVS represents a promising less invasive option for selected severe emphysema patients.